<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

How to Choose Patient-Derived Xenograft (PDX) Models

Starting to write this blog, I realized it could also be titled ‘What to Expect From a Good PDX Database’, as the easiest way to find and choose a model to match your study needs is to search through an online collated database of PDX, which allows for a wide variety of model parameters to be examined.

Essentially, how you choose depends on what you are looking for – a particular cancer subtype, a fusion your inhibitor targets, or maybe drug resistant vs sensitive models. Having a large collection of PDX, collated via background information and searchable through characterization data should make it easy to stratify from a couple of thousand models down to exactly what you need.

Simple Browsing, Searching, and Model Stratification Required

There are many factors which help decide the models you need, both in patient background information and for developed models. Some people want to browse a full collection of breast cancer PDX to choose a panel, others want to directly look at all models treated with cisplatin, for example.

To answer these needs, patient background details and simple model information (pathology, IHC, growth data, treatment data) need collated in a user friendly manner, allowing both browsing and easy stratification. Grouping models by cancer type allows database users to see similar model information side by side, and easily select by browsing factors such as:

  • Patient ethnicity
  • Treatment naïve vs pretreated patients
  • Disease subtype including simple IHC protein expression data
  • Growth rates

Simple searching options can include selecting models (by cancer type or across all cancer types) by:

  • Treated vs untreated models
  • A specific drug treatment
  • Models with profiling data available for more in depth searching

Searching by Characterization Data

Some researchers have specific genetic needs when looking for models, and these should also be accommodated within a PDX database. Historically, characterization data would have been generated by microarray for gene expression and copy number, now this is more likely to be covered by RNAseq and WES, respectively. Databases usually allow searching for:

  • Gene expression
  • Gene copy number
  • Gene mutation
  • Gene fusion
  • miRNA expression

This allows users to select models directly based on the characteristics they need e.g. models across all leukemia types with BCR-ABL fusions, breast and ovarian cancer models with BRCA mutations, or combinations of searches such as lung cancer models with EGFR mutation but normal expression levels, or top 10% of models expressing gene A which are also the bottom 10% of models expressing Gene B. Searches like these need a large proportion of a PDX collection to have been sequenced, but can provide a rapid method to stratify complex needs and find models to fully mimic the clinical situation.

Selecting Models from Tumor Microarrays

Another way to search for models of interest is via TMAs. They allow rapid and high-throughput assay screening and identification of molecular targets, diagnostic, and prognostic markers of interest. This can be at the DNA, mRNA, or protein level, under identical, standardized conditions.

This screening method can be integrated with a PDX database – with models included on premade TMAs highlighted, allowing panels of models to be preselected and then subsequently screened, usually across one cancer type per TMA.

Choosing the right PDX model to match complex study needs may initially seem difficult, hopefully, this blog has shown with the help of a good database it should be a quick and easy process.


Related Posts